CytomX Targets Multibillion-Dollar Market with Varseta-M Registrational Trial
CytomX plans a pivotal registrational study of Varseta-M anti-EpCAM ADC after Phase 1 data showed activity in late-line colorectal cancer with manageable diarrhea from loperamide and budesonide prophylaxis. The company aims to expand Varseta-M into gastric, pancreatic, lung, ovarian and breast tumors by year-end targeting a multibillion-dollar market by 2040.
1. Phase 1 Data Highlights
Phase 1 dose optimization and expansion cohorts in late-line colorectal cancer showed Varseta-M activity with a manageable safety profile. Preliminary progression-free survival metrics appear promising, though additional data are needed to confirm long-term benefits and refine dosing.
2. Pivotal Trial Planning
CytomX is finalizing the size and design of a registrational pivotal study, aiming for a manageable patient cohort that can be executed quickly. Overall survival is expected to serve as the primary endpoint, potentially influencing trial complexity and timeline.
3. Diarrhea Prophylaxis and Safety
Initial use of loperamide prophylaxis was supplemented with budesonide after observing rapid trial enrollment. Budesonide has proven effective, with high patient compliance, supporting its adoption in real-world settings to manage ADC-related diarrhea.
4. Expansion into New Indications
Beyond colorectal cancer, CytomX plans to initiate studies in EpCAM-positive solid tumors—including gastric, pancreatic, lung, ovarian and certain breast cancers—by year-end. The company projects Varseta-M could capture a multibillion-dollar US market opportunity by 2040.